U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Process for preparing ethyl ester of L-DOPA

Patent 5354885 Issued on October 11, 1994. Estimated Expiration Date: Icon_subject December 24, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

3803120

Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
Patent #: 3939253
Issued on: 02/17/1976
Inventor: Bodor ,   et al.

Effervescent enteric coated L-dopa formulation and method of using the same
Patent #: 3961041
Issued on: 06/01/1976
Inventor: Nishimura ,   et al.

Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
Patent #: 4035507
Issued on: 07/12/1977
Inventor: Bodor ,   et al.

Rectally absorbable form of L-dopa
Patent #: 4663349
Issued on: 05/05/1987
Inventor: Repta

Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
Patent #: 4826875
Issued on: 05/02/1989
Inventor: Chiesi

Method of treating parkinson's syndrome Patent #: 4916151
Issued on: 04/10/1990
Inventor: Bey, et al.

Inventors

Assignee

Application

No. 995847 filed on 12/24/1992

US Classes:

560/43, The nitrogen is bonded directly to a ring and is in same side chain as ester function560/45, Oxy in acid moiety562/433, Nitrogen bonded directly to carbon of organic radical (e.g., amino acids, etc.)562/445Phenyl alanines

Examiners

Primary: Cintins, Marianne M.
Assistant: Criares, T. J.

Attorney, Agent or Firm

Foreign Patent References

  • 1364505 GB. 08/13/1974

International Classes

C07C 229/00
A61K 031/195
A61K 031/135

Abstract

A composition which comprises a pharmaceutically acceptable carrier and an active ingredient, such active ingredient comprising L-DOPA ethyl ester in an amount which is at least 97%, by weight, of the active ingredient, and L-DOPA in an amount which is less than 1% by weight of such active ingredient is provided by this invention. This invention also provides a process for preparing such a composition. Further, this invention provides a method of treating a patient suffering from Parkinson's disease which comprises administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of L-DOPA ethyl ester and a pharmaceutically acceptable carrier.

Other References

  • Cooper, D. R., et al. Clin. Neuropharmacol. 7: 89-98 (1984)
  • Fix, J. A., et al., Pharm. Res. 6:501-505 (1989)
  • Juncos, J. L., et al., Neurology 37:1242-1245 (1987)
  • Lai, C. M., et al., J. Pharm. Sci. 62:510-511 (1973)
  • Cooper et al, L-Dopa ester as potential prodrugs: . . . "disease". Journal f Pharmacy and Pharmacology, vol. 39(8) Aug. 198
PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
 
Sign InRegister
Username  
Password   
forgot password?